Kong Lingzhi, Zhang Peng, Li Wang, Yang Yan, Tian Ye, Wang Xujun, Chen Sujun, Yang Yuxin, Huang Tianhao, Zhao Tian, Tang Liang, Su Bo, Li Fei, Liu X Shirley, Zhang Fan
Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
School of Life Science and Technology, Tongji University, Shanghai 200092, China.
Oncotarget. 2016 May 10;7(19):27959-74. doi: 10.18632/oncotarget.8563.
Epigenetic regulation plays an important role in tumor metastasis. KDM1A is a histone demethylase specific for H3K4me2/me1 demethylation, and has been found to be overexpressed in many cancers, including non-small cell lung cancer (NSCLC). However, the role of KDM1A in lung cancer remains unclear. Here, we show that KDM1A promotes cancer metastasis in NSCLC cells by repressing TIMP3 (tissue inhibitor of metalloproteinase 3) expression. Consistently with this, overexpression of TIMP3 inhibited MMP2 expression and JNK phosphorylation, both of which are known to be important for cell invasion and migration. Importantly, knockdown of TIMP3 in KDM1A-deficient cells rescued the metastatic capability of NSCLC cells. These findings were also confirmed by pharmacological inhibition assays. We further demonstrate that KDM1A removes H3K4me2 at the promoter of TIMP3, thus repressing the transcription of TIMP3. Finally, high expression of KDM1A and low expression of TIMP3 significantly correlate with a poor prognosis in NSCLC patients. This study establishes a mechanism by which KDM1A promotes cancer metastasis in NSCLC cells, and we suggest that KDM1A may be a potential therapeutic target for NSCLC treatment.
表观遗传调控在肿瘤转移中起重要作用。KDM1A是一种特异性针对H3K4me2/me1去甲基化的组蛋白去甲基化酶,已发现在包括非小细胞肺癌(NSCLC)在内的许多癌症中过表达。然而,KDM1A在肺癌中的作用仍不清楚。在此,我们表明KDM1A通过抑制TIMP3(金属蛋白酶组织抑制剂3)的表达促进NSCLC细胞中的癌症转移。与此一致,TIMP3的过表达抑制了MMP2的表达和JNK磷酸化,这两者都已知对细胞侵袭和迁移很重要。重要的是,在KDM1A缺陷细胞中敲低TIMP3可挽救NSCLC细胞的转移能力。这些发现也通过药理学抑制试验得到证实。我们进一步证明KDM1A去除TIMP3启动子处的H3K4me2,从而抑制TIMP3的转录。最后,KDM1A的高表达和TIMP3的低表达与NSCLC患者的不良预后显著相关。本研究建立了一种KDM1A促进NSCLC细胞中癌症转移的机制,并且我们认为KDM1A可能是NSCLC治疗的潜在治疗靶点。